Literature DB >> 16979149

Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations.

Cengiz Korkmaz1, Tercan Us, Timuçin Kaşifoğlu, Yurdanur Akgün.   

Abstract

OBJECTIVES: To evaluate frequency of anti-cyclic citrullinated peptide antibodies (anti-CCP) in long-standing rheumatoid arthritis (LsRA) patients and their relationship with extra-articular manifestations of rheumatoid arthritis (RA), in addition to comparing frequency of anti-CCP antibodies in early RA (ERA) and LsRA group. DESIGN AND METHODS: One hundred and fifteen consecutive RA patients were included in the study as having LsRA because their disease duration was longer than 3 years. Thirty-nine consecutive patients with RA were included in the study as having ERA (<3 years). Also, 64 individuals were included in the study as healthy controls to verify the specificity and sensitivity of anti-CCP antibodies. Anti-CCP antibody and rheumatoid factor (RF) were evaluated with enzyme-linked immunosorbent assay kits and standard nephelometry methods, respectively. Extra-articular manifestations were diagnosed by relevant criteria.
RESULTS: The total number of patients with extra-articular manifestations was found to be 45 (39%). No significant difference was found between LsRA group and ERA group in terms of extra-articular manifestations. There were no differences between both groups regarding the number of patients with positive anti-CCP antibodies and the levels of anti-CCP antibodies. In LsRA group, there was a positive correlation between erosion and disease duration (r=0.24, p<0.01), between erosion and RF (r=0.29, p<0.002), and between erosion and anti-CCP antibody (r=0.21, p<0.02). Positive correlations between RF and anti-CCP antibody (r=0.32, p<0.0001), as well as between subcutaneous nodule and lung involvement (r=0.24, p<0.008), were found in the LsRA group. However, no positive correlation could be found between anti-CCP antibody positivity and extra-articular organ involvement, either cumulatively or separately.
CONCLUSIONS: Although anti-CCP antibodies are associated with the severity of the disease and erosion, they do not seem to have much linkage with extra-articular manifestations of RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979149     DOI: 10.1016/j.clinbiochem.2006.06.004

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  22 in total

1.  Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses.

Authors:  Lisa Harlow; Bernadette R Gochuico; Ivan O Rosas; Tracy J Doyle; Juan C Osorio; Timothy S Travers; Carlos C Camacho; Chester V Oddis; Dana P Ascherman
Journal:  Clin Immunol       Date:  2014-08-19       Impact factor: 3.969

2.  The clinical utility of anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.

Authors:  İsmail Şimşek
Journal:  Eur J Rheumatol       Date:  2014-06-01

3.  Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gender, and tabagism in rheumatoid arthritis patients from southern Brazil.

Authors:  Isabela Goeldner; Thelma L Skare; Iara T de Messias Reason; Renato M Nisihara; Marília B Silva; Shirley R da Rosa Utiyama
Journal:  Clin Rheumatol       Date:  2011-02-22       Impact factor: 2.980

4.  The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.

Authors:  Yeliz Özkaya Eker; Ömer Nuri Pamuk; Gülsüm Emel Pamuk; Salim Dönmez; Necati Çakır
Journal:  Eur J Rheumatol       Date:  2014-06-01

5.  A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients.

Authors:  Yan Geng; Wei Zhou; Zhuo-Li Zhang
Journal:  Rheumatol Int       Date:  2011-12-24       Impact factor: 2.631

6.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

7.  Extensive Citrullination Promotes Immunogenicity of HSP90 through Protein Unfolding and Exposure of Cryptic Epitopes.

Authors:  Timothy S Travers; Lisa Harlow; Ivan O Rosas; Bernadette R Gochuico; Ted R Mikuls; Sanjoy K Bhattacharya; Carlos J Camacho; Dana P Ascherman
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

8.  Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis.

Authors:  Oscar-Danilo Ortega-Hernandez; Ricardo Pineda-Tamayo; Aryce L Pardo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2009-03-10       Impact factor: 2.980

9.  Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients?

Authors:  Nikolaos G Papadopoulos; Georgios Z Tsiaousis; Aikaterini Pavlitou-Tsiontsi; Anastasia Giannakou; Vassiliki K Galanopoulou
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 10.  Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies.

Authors:  Y W Song; E H Kang
Journal:  QJM       Date:  2009-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.